港鐵(00066.HK)黃竹坑站第五期物業項目最少獲8份意向書
港鐵(00066.HK)黃竹坑站第五期物業發展項目,今日(22日)下午2時截收發展意向書。現場所見,暫時最少獲8份意向書,包括英皇(00163.HK)、碧桂園(02007.HK)、旭輝(00884.HK)、華懋、中國金茂(00817.HK),及爪哇控股(00251.HK)等。
英皇國際高級物業主任蘇穎菁表示,黃竹坑區內發展潛力大,會觀察條款以及補地價金額決定是獨資或合資入標。
項目位於黃竹坑車廠東面上蓋,屬綜合發展項目,住宅樓面面積上限63.6萬平方呎,預計提供最多1,050伙。市場估值介乎約101.8億至123億元,估計每呎補地價或達1.8萬元。(ek/u) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.